Benzinga | Aug 5, 2020 10:14AM EDT

Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $29

Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and lowers the price target from $31 to $29.